JIN reported an interim net profit of $1.8M, down 28% on the prior corresponding period. After adjusting for international expansion costs in both periods, the underlying 1H’14 net profit of $2.9M was circa 8.5% below 1H’13.

SUD is a drug delivery company focusing on reformulating existing drugs into an oral spray for delivery through the oral mucosa. The company currently has a number of drugs under development including an oral spray for the treatment of malaria in children and oral sprays for migraine, erectile dysfunction, chemotherapy-induced nausea, pulminary arterial hypertension and pre-procedural anxiety

FY15 proved to be a stabilising year after the poor FY14 results. Revenue was up 8.8% with net profit up 34.9%. The increased profit was largely a result of improved gross profit margin, which increased to 54.5% from 48.7% in FY14. The gross profit margin improved due to the sale of higher margin products.

During November 2013, HIG announced the sale of Xstrata’s share of the Frieda River Project to PanAust Limited (PanAust). This update focuses on the new partner agreement and provides a revised valuation based on the revised economics of the project

The company has been appointed as a preferred supplier of prepaid card solutions for the QLD Government. The agreement will be for an initial five year period with the option to extend for an additional four years through two consecutive two year contracts. The company is also undertaking a three month trial with Cash Converters